10 citations
,
October 2010 in “International Journal of Andrology” Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
8 citations
,
June 2020 in “The Journal of Clinical Endocrinology and Metabolism” Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
4 citations
,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
4 citations
,
September 2010 in “Medical Hypotheses”
4 citations
,
September 2006 in “European Journal of Clinical Pharmacology” Finasteride doesn't affect omeprazole metabolism in Japanese people.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
3 citations
,
October 2015 in “Human Psychopharmacology-clinical and Experimental” Finasteride doesn't affect sleep spindles in men.
2 citations
,
July 2025 in “Discover Chemistry.” Alstonia boonei phytochemicals show promise as alternative treatments for BPH with fewer side effects than current drugs.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
2 citations
,
February 2018 in “InTech eBooks” TNF-alpha inhibitors can cause various immune-related skin issues.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
2 citations
,
January 2015 in “Springer eBooks” Environmental factors and exposure to toxins may contribute to male infertility by affecting sperm and hormone function.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
August 2024 in “Biomolecules & Therapeutics” A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.
127 citations
,
December 2005 in “Experimental Dermatology” Stress can stop hair growth in mice, and treatments can reverse this effect.
125 citations
,
September 2001 in “The FASEB Journal” Stress can cause hair loss by negatively affecting hair follicles and this effect might be reversed with specific treatments.
39 citations
,
May 2014 in “Frontiers in Pharmacology” Special immune cells called Tregs can help prevent lung scarring by blocking a specific growth factor.
38 citations
,
June 2005 in “Matrix Biology” Minoxidil affects collagen-related genes, potentially helping treat fibrosis.
28 citations
,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
18 citations
,
September 2021 in “Journal of Neuroendocrinology” Neurosteroids can influence behavior by modulating brain inhibition, with potential for treating psychiatric disorders.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
3 citations
,
February 2019 in “Journal of Cosmetic Dermatology” The effects of estrogen on human scalp hair growth are unclear and need more research.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.